Skip to main content
TipRanks
Go Ultimate75% OFF

PharmaNutra SpA (PHN) AI Stock Analysis

13 Followers
IT:PHN

PharmaNutra SpA

(Milan:PHN)

Select Model
Rating:66Neutral
Price Target:EUR 91.00â–²(5.81% Upside)
Action:reiterated
Date:11/13/26

The score is driven primarily by solid balance-sheet strength and strong recent cash generation, offset by a material red flag in TTM operating profitability (negative gross and operating margins despite positive net income). Technically the trend is positive but looks overbought, and the elevated P/E with only a modest dividend yield reduces valuation support.

Positive Factors
Revenue GrowthRevenue growth of nearly 17% indicates expanding demand for PharmaNutra’s nutraceutical portfolio and increasing commercial reach. If sustained, this top-line momentum can support operating scale, reinforce distribution relationships, and provide a foundation for continued investment in branded products and formulations.
Negative Factors
Operating ProfitabilityThe sharp deterioration in gross, EBIT, and EBITDA margins weakens confidence in the underlying economics of the current business. Unless operating profitability recovers, revenue growth may not translate into durable earnings or cash generation, limiting the sustainability of recent financial performance.

PharmaNutra SpA (PHN) vs. iShares MSCI Italy ETF (EWI)

-20%0%20%40%60%80%100%IT:PHN+74.31%EWI+14.63%Dec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
Market Cap
EUR 798.57M
Dividend Yield
1.44%
Average Volume (3M)
15.17K
Price to Earnings (P/E)
34.6
Beta (1Y)
0.42
Revenue Growth
16.89%
EPS Growth
32.34%
Country
Italy
Employees
128
Sector
Healthcare
Sector Strength
51
Industry
Drug Manufacturers - Specialty & Generic

PharmaNutra SpA Business Overview & Revenue Model

Company Description

Pharmanutra S.p.A. functions as a pharmaceutical and nutraceutical enterprise, focusing on the research, development, design, and marketing of nutritional supplements and medical devices. Its market reach extends across Italy, other parts of Europe,...

How the Company Makes Money

PharmaNutra makes money primarily by selling nutraceutical and dietary supplement products and related formulations through two main channels: (1) sales of its own branded products to distributors, pharmacies, and other commercial partners in its ser...

PharmaNutra SpA Financial Statement Overview

Summary

Balance sheet and cash flow are solid (low leverage around 0.26x debt-to-equity, strong ROE, and strongly positive TTM operating/free cash flow). The main risk is earnings quality: TTM operating profitability deteriorated sharply (negative gross/EBIT/EBITDA margins) despite a healthy net margin, suggesting reliance on non-operating items that may be less repeatable.

Income Statement

62Positive

Balance Sheet

78Positive

Cash Flow

74Positive
Financial statement breakdown
BreakdownTTMDec 2025Dec 2024Dec 2023Dec 2022Dec 2021
Income Statement
Total Revenue148.27M131.69M116.15M101.03M83.39M68.14M
Gross Profit-9.50M29.71M82.79M48.95M30.17M32.15M
EBITDA-8.18M34.21M32.01M26.48M24.61M19.84M
Net Income22.97M20.00M16.61M12.83M15.05M13.77M
Balance Sheet
Total Assets130.92M125.23M117.47M112.44M100.16M71.36M
Cash, Cash Equivalents and Short-Term Investments25.12M30.61M29.10M25.12M26.86M33.94M
Total Debt20.02M20.51M24.27M28.02M17.73M6.35M
Total Liabilities55.28M53.99M55.27M58.04M49.21M26.27M
Stockholders Equity75.78M71.35M62.16M54.41M50.95M45.08M
Cash Flow
Free Cash Flow18.98M16.43M16.25M-1.16M-8.69M15.43M
Operating Cash Flow24.98M19.56M20.50M12.09M14.47M20.41M
Investing Cash Flow-7.47M-3.36M-2.21M-14.70M-23.71M-5.54M
Financing Cash Flow-14.87M-13.12M-21.59M-516.00K1.89M-1.92M

PharmaNutra SpA Technical Analysis

Technical Analysis SentimentPositive
Last Price86.00

Price Trends

50DMA74.00Positive
100DMA79.08Positive
200DMA78.40Positive

Market Momentum

MACD2.97Negative
RSI76.76Negative
STOCH93.02Negative

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For IT:PHN, the sentiment is Positive. The current price of 86.00 is above the 20-day moving average (MA) of 75.05, above the 50-day MA of 74.00, and above the 200-day MA of 78.40, indicating a bullish trend. The MACD of 2.97 indicates Negative momentum. The RSI at 76.76 is Negative, neither overbought nor oversold. The STOCH value of 93.02 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for IT:PHN.

PharmaNutra SpA Peers Comparison

Overall Rating

UnderperformOutperform
Sector (51)

Financial Indicators

IT:PHN against its peers
NameOverall RatingMarket CapP/E RatioROEDividend YieldRevenue GrowthEPS Growth
IT:PHNIT:PHN66NeutralEUR 807.39M34.60―1.44%16.89%32.34%
Sector *51Neutral$7.86B-0.30-43.30%2.27%22.53%-2.21%
IT:EUKIT:EUK42NeutralEUR 11.14M24.38――3.21%―

* Healthcare Sector Average

Performance Comparison

-25%0%25%50%75%IT:PHNIT:GHCIT:ARBSIT:EUKIT:COSMOIT:SVSDec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
IT:PHN and its peers over the selected period
Show on chartTickerCompany NamePriceChange% Change
IT:PHNPharmaNutra SpA86.0036.1772.59%
IT:GHCGarofalo Health Care S.P.A.5.200.142.79%
IT:ARBSArterra Bioscience SpA3.000.134.46%
IT:EUKEukedos S.p.A.0.48-0.26-35.14%
IT:COSMOFarmacosmo S.P.A.0.41-0.01-1.67%
IT:SVSSvas Biosana S.p.A.8.00-0.47-5.54%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.

Date of analysis: Nov 13, 2026